The Use of Clinical Endpoints in the ZUMA-3 Trial

Jul 14, 2021

Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.

This content originally appeared on our sister site, OncLive.

First Patient Dosed in Phase 1/1b Trial of PRGN-3007 CAR-T Cell Therapy in Solid Tumors, Hematologic Malignancies

April 1st 2023

First Patient Dosed in Phase 1/1b Trial of PRGN-3007 CAR-T Cell Therapy in Solid Tumors, Hematologic Malignancies

April 1st 2023

CGTLive’s Weekly Rewind – March 31, 2023

March 31st 2023

Caribou Biosciences Provides Updates on Allogeneic CAR-T Clinical Trials

March 31st 2023

First Patient With HPV16+ Solid Tumors in SQZ-AAC-HPV Trial Achieves CR

March 30th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 29, 2023

March 29th 2023

Ball in FDA’s Court for Lifileucel BLA in Advanced Melanoma

March 28th 2023

First Patient Dosed in Phase 1/1b Trial of PRGN-3007 CAR-T Cell Therapy in Solid Tumors, Hematologic Malignancies

April 1st 2023

CGTLive’s Weekly Rewind – March 31, 2023

March 31st 2023

Caribou Biosciences Provides Updates on Allogeneic CAR-T Clinical Trials

March 31st 2023

First Patient With HPV16+ Solid Tumors in SQZ-AAC-HPV Trial Achieves CR

March 30th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 29, 2023

March 29th 2023

Ball in FDA’s Court for Lifileucel BLA in Advanced Melanoma

March 28th 2023

Related Content

First Patient Dosed in Phase 1/1b Trial of PRGN-3007 CAR-T Cell Therapy in Solid Tumors, Hematologic Malignancies

April 1st 2023

Article

Precigen’s investigational UltraCAR-T therapy is being assessed in a dose-escalation and -expansion study that will include patients with solid tumors, chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma.